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Dear Editor,

 {#ijc31888-sec-0001}

We read with great interest the article by Kim *et al*.[1](#ijc31888-bib-0001){ref-type="ref"} regarding the role of prospero homeobox protein 1 (PROX1) and telomerase reverse transcriptase (TERT) in hepatocellular carcinoma (HCC); their study reported that *PROX1* expression mediated *TERT* activity differently in accordance with the status of viral infection in HCC. Interestingly, *TERT* and *PROX1* mRNA expression were positively correlated in non‐B viral HCCs; however, this correlation was not observed in B viral HCCs. Using same approach, we analyzed the correlation between *TERT* and *PROX1* mRNA expression in various cancers including HCC, based on The Cancer Genome Atlas (TCGA) data from OncoLnc and cBioPortal.

Expression data were downloaded from TCGA\'s data portal (<https://tcga-data.nci.nih.gov/tcga/>) on July, 2018.[2](#ijc31888-bib-0002){ref-type="ref"} TCGA data indicated that *TERT* mRNA expression levels did not correlate with those of *PROX1* mRNA (*r* = ‐0.041, *p* = 0.443, Fig. [1](#ijc31888-fig-0001){ref-type="fig"} *a*). When stratified by B viral status, there was no association between *TERT* and *PROX1* expression (Fig. [1](#ijc31888-fig-0001){ref-type="fig"} *b*). Interestingly, the median values of TERT and *PROX1* expression in HCCs were high exclusively in TCGA data. Therefore, we investigated this association in other cancers presented on TCGA portal. Unexpectedly, *TERT* and *PROX1* mRNA expression levels were correlated in several cancer types, including melanoma, esophageal, head and neck, and lung cancers (Fig. [1](#ijc31888-fig-0001){ref-type="fig"} *b*). Although this association was not observed previously in HCC,[1](#ijc31888-bib-0001){ref-type="ref"} *PROX1* may be an important activator of *TERT* in some cancers. Regarding studies on *TERT* promoter mutation, a common single nucleotide polymorphism, rs2853669, and hepatitis B virus X were not included in HCC analysis of TCGA data, thereby necessitating further comprehensive analyses.
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Furthermore, the prognostic value of *PROX1* mRNA expression was analyzed in various cancers on the basis of TCGA data. In most cancers including HCC, *PROX1* did not have a prognostic value (Fig. [1](#ijc31888-fig-0001){ref-type="fig"} *c*). However, *PROX1* downregulation indicated a poorer prognosis exclusively in melanoma (*p* = 0.048). The *TERT* promoter is one of the most frequent mutation sites in HCC and may be an essential modulator of *TERT* expression in cancers.[3](#ijc31888-bib-0003){ref-type="ref"} Moreover, *TERT* expression is a robust prognostic marker; however, the detailed mechanism underlying *TERT* regulation yet remains controversial.[4](#ijc31888-bib-0004){ref-type="ref"} As observed in the current and in previous studies, a positive correlation between *TERT* and *PROX1* expression in certain cancers suggested that PROX1 probably regulates TERT in an activity‐dependent manner with other genetic changes.[1](#ijc31888-bib-0001){ref-type="ref"} The biological functions of *PROX1*‐ and *TERT*‐associated gene alterations are of great interest for further studies in cancer.

Yours sincerely,
